Literature DB >> 33922157

A Perspective on Imiquimod Microneedles for Treating Warts.

Tsu-Man Chiu1,2,3, Ping-Chun Hsu2, Mohd Yaqub Khan2, Cheng-An J Lin2, Chun-Hung Lee2,4, Tsai-Ching Hsu3,5, Min-Hua Chen2,4, Nobutaka Hanagata6.   

Abstract

Warts are a common skin problem and are caused by infection with a virus. Warts are currently mainly treated by therapies involving ablating tissue or interrupting cellular division. However, all these existing treatments are either invasive or cause skin pain and tissue destruction. Imiquimod is a synthetic compound that belongs to the imidazoquinolinone family. It has been successfully used as a topical drug to treat external anogenital warts. However, topical imiquimod cream for warts is restricted by low skin permeability, and several side effects such as itching, pain, and erosions occur most frequently following topical treatment. Microneedle technology, a minimally invasive drug delivery system, has the potential to overcome the barrier of the stratum corneum. This technique would also offer a painless treatment choice and provide personalized therapies. In the study, we loaded imiquimod within dissolving microneedles using the molding method. Gelatin was used as a structural material for microneedle formation without adding a crosslinker. To our knowledge, this is the first study of using dissolving microneedles and exploring their utilization with imiquimod for the treatment of warts. First, we added fluorescent dye and trypan blue into the microneedles to evaluate the status of drugs in the microneedles and the degradation property of microneedles made of gelatin, respectively. Here we also prove the strength of the imiquimod microneedles and study their capability to penetrate the skin. The results show no apparent differences in mechanical failure after an additional imiquimod-loaded. Besides, we provide evidence that imiquimod microneedles induce secreted embryonic alkaline phosphatase (SEAP) in the RAW 264.7 macrophages. Gelatin does not affect the imiquimod in microneedles; a similar immune response was affected by the imiquimod alone or imiquimod complexed with gelatin. Our research demonstrates a proof of concept of using imiquimod microneedles for future warts treatment.

Entities:  

Keywords:  dissolving microneedles; gelatin; imiquimod; immunomodulator; warts

Year:  2021        PMID: 33922157     DOI: 10.3390/pharmaceutics13050607

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  27 in total

1.  Mechanism of action of imiquimod 5% cream in the treatment of anogenital warts.

Authors: 
Journal:  Prim Care Update Ob Gyns       Date:  1998-07-01

2.  Potentiality of gelatin microsphere as immunological adjuvant.

Authors:  R Nakaoka; Y Tabata; Y Ikada
Journal:  Vaccine       Date:  1995-05       Impact factor: 3.641

Review 3.  Microneedle characterisation: the need for universal acceptance criteria and GMP specifications when moving towards commercialisation.

Authors:  Rebecca E M Lutton; Jessica Moore; Eneko Larrañeta; Stephen Ligett; A David Woolfson; Ryan F Donnelly
Journal:  Drug Deliv Transl Res       Date:  2015-08       Impact factor: 4.617

4.  A microneedle-based method for the characterization of diffusion in skin tissue using doxorubicin as a model drug.

Authors:  Iman Mansoor; Jacqueline Lai; Sahan Ranamukhaarachchi; Veronika Schmitt; Dana Lambert; Jan Dutz; Urs O Häfeli; Boris Stoeber
Journal:  Biomed Microdevices       Date:  2015       Impact factor: 2.838

5.  Efficacy of a bleomycin microneedle patch for the treatment of warts.

Authors:  Ha Ryeong Ryu; Hye-Rin Jeong; Hye-Seung Seon-Woo; Jung Soo Kim; Seul Ki Lee; Hee Joo Kim; Jin Ok Baek; Jung-Hwan Park; Joo Young Roh
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

6.  Preparation and in vitro evaluation of imiquimod loaded polylactide-based micelles as potential vaccine adjuvants.

Authors:  Gloria Jiménez-Sánchez; Vincent Pavot; Christelle Chane-Haong; Nadège Handké; Céline Terrat; Didier Gigmes; Thomas Trimaille; Bernard Verrier
Journal:  Pharm Res       Date:  2014-09-24       Impact factor: 4.200

7.  Intradermal Delivery of an Immunomodulator for Basal Cell Carcinoma; Expanding the Mechanistic Insight into Solid Microneedle-Enhanced Delivery of Hydrophobic Molecules.

Authors:  Akmal Sabri; Jane Ogilvie; John McKenna; Joel Segal; David Scurr; Maria Marlow
Journal:  Mol Pharm       Date:  2020-06-30       Impact factor: 4.939

8.  Efficacy of imiquimod-based transcutaneous immunization using a nano-dispersed emulsion gel formulation.

Authors:  Pamela Stein; Karsten Gogoll; Stefan Tenzer; Hansjörg Schild; Stefan Stevanovic; Peter Langguth; Markus P Radsak
Journal:  PLoS One       Date:  2014-07-15       Impact factor: 3.240

9.  Delivery Strategies for Skin: Comparison of Nanoliter Jets, Needles and Topical Solutions.

Authors:  Katharina Cu; Ruchi Bansal; Samir Mitragotri; David Fernandez Rivas
Journal:  Ann Biomed Eng       Date:  2019-10-15       Impact factor: 3.934

Review 10.  Recent advances of microneedles for biomedical applications: drug delivery and beyond.

Authors:  Jian Yang; Xinli Liu; Yunzhi Fu; Yujun Song
Journal:  Acta Pharm Sin B       Date:  2019-04-04       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.